



Cefquinome shows a higher impact on the pig gut microbiome and resistome compared to ceftiofur

Sofie Rutjens, Nick Vereecke, Jannes Sauer, Siska Croubels, Mathias Devreese

► To cite this version:

Sofie Rutjens, Nick Vereecke, Jannes Sauer, Siska Croubels, Mathias Devreese. Cefquinome shows a higher impact on the pig gut microbiome and resistome compared to ceftiofur. *Veterinary Research*, 2023, 54 (1), pp.45. <10.1186/s13567-023-01176-8>. <hal-04519537>

HAL Id: hal-04519537

<https://hal.science/hal-04519537v1>

Submitted on 25 Mar 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

RESEARCH ARTICLE

Open Access



Cefquinome shows a higher impact on the pig gut microbiome and resistome compared to ceftiofur

Sofie Rutjens¹ , Nick Vereecke^{2,3}, Jannes Sauer², Siska Croubels¹ and Mathias Devreese^{1*}

Abstract

Cephalosporins are licensed for treatment of severe bacterial infections in different species. However, the effect of these antimicrobials on the fecal microbiome and potential spread of resistance-associated genes causes great concern. This highlights the need to understand the impact of cephalosporins on the porcine fecal microbiome and resistome. A combination of long-read 16S rRNA gene and shotgun metagenomic sequencing was applied to investigate the effect of conventional treatment with either ceftiofur (3 mg.kg⁻¹ intramuscular, 3 consecutive days) or cefquinome (2 mg.kg⁻¹ intramuscular, 5 consecutive days) on the porcine microbiome and resistome. Fecal samples were collected from 17 pigs (6 ceftiofur treated, 6 cefquinome treated, 5 control pigs) at four different timepoints. Treatment with ceftiofur resulted in an increase in Proteobacteria members on microbiome level, while on resistome level selection in *TetQ* containing *Bacteroides*, *CfxA6* containing *Prevotella* and *bla*_{TEM-1} containing *Escherichia coli* was observed. Cefquinome treatment resulted in a decline in overall species richness (α -diversity) and increase in Proteobacteria members. On genus level, administration of cefquinome significantly affected more genera than ceftiofur (18 vs 8). On resistome level, cefquinome resulted in a significant increase of six antimicrobial resistance genes, with no clear correlation with certain genera. For both antimicrobials, the resistome levels returned back to the control levels 21 days post-treatment. Overall, our study provides novel insights on the effect of specific cephalosporins on the porcine gut microbiome and resistome after conventional intramuscular treatment. These results might contribute to better tailoring of the most ideal treatment strategy for some bacterial infections.

Keywords Veterinary cephalosporins, gut microbiome, resistome, ARGs, porcine feces, 16S rRNA sequencing, shotgun sequencing, metagenomics

Introduction

According to the Centers for Disease Control and Prevention (CDC), antimicrobial resistance (AMR) will cause approximately 10 million annual deaths by 2050, making it one of the top 10 threats to global health [1, 2]. Although the increase in AMR was seen even before the introduction of antimicrobials, there is a general agreement that the increase in AMR is strongly related to the use and especially the misuse of antimicrobials [3]. Concurrent use of antimicrobials in both humans and animals drives the emergence and transmission of acquired resistance only further [4]. The World Health Organization

Handling editor: Marcelo Gottschalk.

*Correspondence:

Mathias Devreese

Mathias.Devreese@UGent.be

¹ Department of Pathobiology, Pharmacology and Zoological Medicine, Laboratory of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium

² PathoSense BV, 2500 Lier, Belgium

³ Department of Translational Physiology, Infectiology and Public Health, Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, 9820 Merelbeke, Belgium



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(WHO) has made a ranking of antimicrobials that are of critical importance to human medicine. The prudent use of these antimicrobials, especially in veterinary medicine, should help to preserve the efficacy of the available antimicrobials. Quinolones, third- and fourth-generation cephalosporins, macrolides and ketolides, and glycopeptides are considered antimicrobials of highest priority [5]. Cephalosporins belonging to the 3rd and 4th generation (e.g. ceftriaxone, cefodizine, cefcapene, etc.) represent antimicrobials often used as a last resort to treat severe, invasive infections in human medicine [6, 7]. Consequently, the administration of 3rd and 4th generation cephalosporins in veterinary medicine is under scrutiny [8]. Though, their overall use in veterinary medicine is low [9]. Since, the fear of potential ineffectiveness of cephalosporins in human medicine resulted in a voluntary ban on their veterinary use in some countries, which resulted in a reduction in associated resistance levels [10, 11]. Still, third- and fourth-generation cephalosporins were shown to be the sole effective pharmacotherapy against some veterinary pathogens (e.g. treatment of foal septicaemia caused by *Escherichia coli*). Banning these antimicrobials could, therefore, result in increased animal suffering and decreased welfare [12–14]. In pig production, these cephalosporins are administered for the treatment of post-partum dysgalactia syndrome, respiratory diseases and *Streptococcus suis* infections [13, 15]. To date, alternatives, such as less critical antimicrobials can often still be administered to treat these infections in pigs as limited acquired AMR has been observed [13]. However, it is of utmost importance to gain better understanding of these cephalosporins and their impact on AMR dissemination after administration to rationalize their use.

Third- and fourth-generation cephalosporins are administered intramuscularly because of their low oral bioavailability. Interestingly, this route of administration prevents direct exposure of the gastro-intestinal tract to these antimicrobials, however, after absorption they may partly get excreted into the intestinal tract [16]. Studies have confirmed the selective effect on resistance of these third- and fourth-generation cephalosporins on the gut microbiome, and especially on the resistance selection in *Escherichia coli* [17, 18]. These findings raised concern on the spread of associated resistance genes found in commensal bacteria of animals to pathogenic bacteria in humans via food and the environment [19]. Judicious use of antibiotics requires not only knowledge on the impact of the treatment on target pathogens or indicator bacteria, such as *Escherichia coli*, it is also important to obtain knowledge on the effect on the overall gut microbiome and changes in its associated resistome. To date, little information on this complex matter is available. Some

studies provide data on the effect of the administration of a single dose, however, no information is available on the impact of a full relevant treatment schedule on the microbiome and resistome of pigs [20–22]. This lack of information limits the possibility for well-founded treatment decisions and administration schemes that take dissemination of AMR-associated genes into account, as well as potential discrepancies between different cephalosporins.

Building on our previous preliminary findings, a combinational metagenomic analysis was applied to determine the effect on the microbiome and resistome after a full treatment schedule with two important veterinary cephalosporins, ceftiofur and cefquinome [16]. Here, long-read nanopore 16S rRNA gene sequencing and associated diversity and composition analyses were performed. This was combined with long-read nanopore shotgun sequencing to study the differential abundance in antimicrobial resistance genes (ARGs). Together the results of these two analyses delivered a well-founded overview of the effect of these antimicrobials on the porcine gut microbiome and resistome. The study design included a control group, to adjust the results for age-related changes in the microbiome and resistome.

Materials and methods

Animal trial

The animal trial was approved by the ethical committee of the Faculty of Veterinary Medicine and of Bioscience Engineering of Ghent University (EC 2021-107). Animal care complied with the Belgian and European legislation on animal welfare and ethics [23, 24].

A group of 17 healthy, stress-resistant 7-week-old pigs (9 male, 8 female, Landrace×Large White×Maximus, Seghers Hybrid®, Wuustwezel, Belgium) of $18.0 \text{ kg} \pm 1.4$ (standard deviation) kg body weight, were separated into two groups of 6 pigs and one group of 5 pigs. Each group was housed in a different adjacent stable and each pig was housed individually to prevent contamination and coprophagy between the groups and different pigs. The pigs had ad libitum access to water and were fed twice daily (Biggispeen Premium®, Aveve, Leuven, Belgium). Before the start of the treatment, the pigs were acclimatized for 10 days.

Group one, consisting of six pigs (three male, three female) received an intramuscular injection in the biceps femoris of cefquinome at $2 \text{ mg} \cdot \text{kg}^{-1}$ body weight at the same timepoint on 5 consecutive days, in accordance with the leaflet (Ceffect®, Emdoka, Hoogstraten, Belgium). The second group of six pigs (three male, three female) was administered 1 mL of a physiological saline solution at the same timepoint as group one on the first 2 days, to mimic treatment handling. The following

3 days they received an intramuscular dose in the biceps femoris of ceftiofur at 3 mg.kg⁻¹ body weight at the same timepoint, in accordance with the leaflet (Excenel flow®, Zoetis, Louvain-la-Neuve, Belgium). Group three, the control group, consisted of five pigs (three male, two female) and received an intramuscular injection in the biceps femoris with 1 mL of a physiological saline solution for 5 consecutive days. Fresh feces (1 g) of each pig was sampled by collection of fresh fecal droppings in a cleaned stable on the morning before the start of the 5 day treatment period (BT), on the evening on the last day of treatment (ET), and on the morning at one and three weeks (7d and 21d) post-treatment (pt). The center of the dropping was subsampled to ensure the accuracy of the bacterial composition. Figure 1 depicts the sampling timeline during the animal trial. The fecal samples were stored at ≤ -70 °C until analysis.

DNA extraction, library preparation and sequencing

DNA extraction was performed on 250 mg feces using the QIAamp PowerFaecal Pro DNA Kit (QIAGEN, Antwerp, Belgium) as per manufacturer's instructions. DNA concentration and purity was measured by evaluating the $A_{260/280}$ and $A_{260/230}$ absorbances on a Nanodrop spectrophotometer. All samples were subjected to an additional magnetic bead clean-up using CleanNGS (CleanNA, Waddinxveen, the Netherlands). The cleaned DNA was subsequently subjected to targeted 16S rRNA gene amplification and shotgun sequencing to identify the bacterial diversity and relative abundance, and the presence of AMR genes, respectively. The integrity of the 16S rRNA gene fragments was visually validated with gel electrophoresis. For 16S rRNA gene and shotgun sequencing library preparations, the SQK-16S024 and SQK-RBK110-96 were used, respectively (ONT; Oxford, UK). In both instances manufacturer's instructions were followed. Finally, the libraries, containing 24 and 12 barcoded samples per library, respectively, were loaded onto a R9.4.1 flow cell prior to sequencing on a GridION sequencer for 36 h.

Sequenced data processing and statistical analysis

After sequencing of the 16S rRNA gene fragments, classification was done using the state-of-the-art emu

software [25, 26]. Base calling and demultiplexing was performed in real-time using the “super accurate” base calling model in Guppy (v6.2.7; ONT) and were quality filtered using NanoFilt (v2.7.1; [27]). The reads were classified to their closest matching hit and classified up to species level. Filtering criteria were determined based on the overall number of classified reads. A threshold of 7500 classified reads was set to assign phylum, family, or genus. The raw data resulting from the shotgun sequencing were taxonomically classified using Kraken2 (v2.0.9; k2_pluspf_20210127; [28]). These taxonomically binned reads were then used to independently search for both ARGs and plasmid replicons using the Comprehensive Antimicrobial Resistance Database (CARD) [29] and PlasmidFinder [30] respectively. Actual screening was performed using Abricate (v1.0.1) [31] with default settings and at a minimum coverage and nucleotide identity of 80% and 60%, respectively. Final ARG abundances were generated per bacterial taxon and per sample as well as identifying reads harbouring both gene hits for plasmid replicons and ARGs. The raw sequencing datafiles are available on the European Nucleotide Archive (ENA) under project PRJEB61541 and accessions ERS1494721-ERS14949789 (Additional file 1).

For 16S rRNA gene data, the α -diversity was analyzed based on the Shannon index (SI) using genus-level classifications. For the statistical comparison of the diversity index (Shannon index) between the different sampling points of each group, a Kruskal–Wallis test was done followed by a Wilcoxon rank sum test. Log₂ fold changes in abundance (of 16S rRNA classified genera and shotgun ARGs) within each treatment group (16S rRNA) or between each treatment group and the control group (shotgun ARGs) at a given sampling point were determined by the negative binomial generalized linear model in the DESeq2 package (V1.32.0) in R (V4.1.2) [32]. The corresponding heatmap of the Log₂ fold changes of the genera was visualized by using the Heatmap function in the R package complexHeatmap (V2.8.0) [33]. The permutational multivariate analysis of variance in microbiome and resistome was quantified by pairwise comparison of the Bray–Curtis dissimilarity matrices, using the adonis2 function in the R package vegan (V2.6.2) [34]. A corresponding Principal Coordinates




Figure 1 Timeline of the four sampling points during the animal trial.

Analysis (PCoA) was visualized with the ggplot2 package (V3.3.6) and a correlation-coefficient analysis was performed for each sampling point using the envfit function in the vegan package [35]. To avoid loss of potentially interesting results, statistical significance was tested at corrected P -values ≤ 0.10 (Bonferroni correction—Shannon index, FDR-correction—other statistics).

Results

16S rRNA sequencing of the 68 porcine fecal samples resulted in an average of 81 559 ($\pm 18\ 650$) reads with an N_{50} length of 1484 (± 61) nucleotides (Additional file 1). Whilst shotgun sequencing resulted in an average of 241 326 ($\pm 121\ 660$) reads with an N_{50} length of 4023 (± 893) nucleotides (Additional file 2). Based on the rarefaction curves of the 16S rRNA gene sequencing, a cut-off of 7500 reads was set, which resulted in a satisfactory taxon richness for all samples (Additional file 3).

Impact on diversity

The Shannon index showed that the evenness of the fecal microbiota in the animals of the control group fluctuated over time, though no significant alterations were identified at any of the different timepoints. For the animals receiving ceftiofur, a comparable fluctuation could be observed. While an apparent decrease in SI was observed at 21 days post-treatment (dpt) for the ceftiofur treated

group, no statistical significance was observed. For the animals of the cefquinome treatment group, a significant decline in SI was detected between the ET (SI 3.5229 ± 0.1375) and 7 dpt samples (SI 3.2478 ± 0.1519 , Bonferroni-corrected P -value 0.026), which returned back to the initial end of treatment levels by 21 dpt (SI 3.5825 ± 0.0514 , Bonferroni-corrected P -value 0.006) (Figure 2).

Impact on taxonomic profiling

The taxonomic profiles of the fecal samples for each sampling point per group is visualized in Figure 3. At the phylum level, Firmicutes was distinctly the most abundant phylum in the porcine microbiome, comprising almost 90% of the total microbial community (Figure 3A). The other 10% consists mainly of Bacteroidetes and Proteobacteria. In the cefquinome group a decrease in abundance of Firmicutes accompanied by an increase in Bacteroidetes was observed at 21 dpt, which did not occur in the control or ceftiofur group. On genus level (Figure 3B), *Clostridium* was the most abundant genus before the start of the antimicrobial treatment, followed by *Blautia* and *Lactobacillus*. The genus composition at the end of treatment is comparable between the control group and the ceftiofur group. However, in the cefquinome group, a smaller amount of *Lactobacillus* was measured, while the levels of *Christensenella* and




Figure 2 Alpha diversity analysis (Shannon Index) of the fecal porcine microbiome at genus level. Box-plots of the Shannon index are shown. *Bonferroni-corrected P -value ≤ 0.10 . Following either ceftiofur treatment: 3 mg.kg^{-1} intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg^{-1} intramuscular, 5 consecutive days. (BT = Before-treatment ($n = 17$), ET = End of Treatment, 7d = 7 days post-treatment, 21d = 21 days post-treatment).




Figure 3 Phylum and genus abundances. **A** Mean relative abundances at the phylum level in the porcine fecal microbiome based on 16S rRNA gene analysis. **B** Top 21 most abundant genera in the porcine fecal microbiome based on 16S rRNA gene analysis. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days. (BT=Before-treatment, ET=End of Treatment, 7d=7 days post-treatment, 21d=21 days post-treatment).

Oscillibacter were relatively higher as compared to the control and ceftiofur group at this timepoint. Over time an increase in *Clostridium* could be observed in the control group, which could also be observed in the ceftiofur group. For cefquinome, this increase could be observed at the first two sampling points, but was followed by a drop at 21 days post-treatment.

Differential abundance analyses of the taxonomic assignments at the genus level were performed using DESeq2. This showed a significant impact of the antimicrobial treatments on the porcine fecal microbiome during the studied sampling period. Genera belonging to the

Firmicutes phylum were most affected by both time and treatment, followed by Bacteroidetes and Proteobacteria (Figure 4A, Additional file 4). Of interest is the remarkable impact on Proteobacteria following both ceftiofur and cefquinome treatment, which is not detected in the control group. However, in the control group Kiritimatiellaeota and Lentisphaerae belong to the affected phyla, which is not the case in the treatment groups. Following cefquinome treatment, some samples show an increase in Elusimicrobia at 21 dpt. On genus level it could be observed that in both control and ceftiofur group at 7 dpt the significant impact was limited to a small number of




Figure 4 Impact of time and treatment on the differential abundances of the genera in the porcine fecal microbiome. **A** Bar plot showing the number of affected genera over the course of the study. **B** Heatmaps showing the change in affected genera between the different time points in each studied group and colour labelled according to their corresponding phylum. Changes following either ceftiofur treatment: 3 mg. kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days. Red shades indicate an increase in abundance, while blue shades indicate a decrease. (BT = Before-treatment, ET = End of Treatment, 7d = 7 days post-treatment, 21d = 21 days post-treatment).

genera. Four genera were affected because of time, and eight were affected because of time and ceftiofur treatment. More important, for cefquinome 18 genera were affected by time and antimicrobial administration at 7 dpt, with a significant (FDR-corrected P -value < 0.10) increase in the abundance of 11 genera, of which 10 belonged to the Firmicutes phylum. Also, a significant reduction of seven genera was observed, of which six belonged to the Firmicutes phylum (Figure 4B). In general, the number of affected genera between 7 dpt samples and the 21 dpt samples remained similar to the affected number between the end of treatment and 7 dpt samples.

Microbiome profile variations

Permutational multivariate analysis of variance using the Bray–Curtis distance matrix indicated that the combination of time and antimicrobial administration could significantly alter the profile of the relative abundance of genera on all sampling points in comparison to the profile in the blank samples (i.e. samples taken of all pigs before treatment) (Additional file 5: Blank vs ET_CT, etc.; FDR-corrected P -value < 0.10). This is in line with the minimal overlap of the before-treatment samples with all other sampling points displayed on the PCoA's (Figures 5A, B). However, for ceftiofur no significant alteration could be observed between the samples of the ceftiofur group




Figure 5 Principal Coordinates Analysis (PCoA) using the Bray–Curtis dissimilarity index showing changes in microbiome profiles. **A** Control group and ceftiofur group. **B** Control group and cefquinome group. The arrows depict a significant influential genus per quadrant of the graph. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days. (ET = End of Treatment, 7d = 7 days post-treatment, 21d = 21 days post-treatment).

and the control group at the same timepoints (ET_Cont vs ET_CT, etc.) suggesting that the observed difference between the before-treatment levels and the levels at the different sampling points after ceftiofur treatment is mainly influenced by time. This is visualized by the consistent overlap of the control samples and ceftiofur samples for each sampling point. Interestingly, the data did indicate a significant impact of cefquinome immediately at the end of treatment (ET) (Additional file 5: Adonis R2 0.3498, FDR-corrected P -value 0.0036), which is in line with the separation of the samples belonging to either the cefquinome group or the control group at the end of treatment displayed on the PCoA plots (Figure 5B).

Correlation-coefficient analysis of the top 21 most abundant microbial genera resulted in a list of influential genera that drive the observed divergence among the different datapoints (Additional file 6). For each quadrant, a significant influential genus based upon the R^2 value has been depicted on the PCoA (Figure 5). For ceftiofur, *Lactobacillus* and *Clostridium* were the main drivers (R^2 0.9180 and 0.8083, respectively), followed by *Blautia* and *Oscillibacter*. In the cefquinome treatment group, mainly *Lactobacillus* and *Blautia* were drivers of divergence (R^2 0.7496 and 0.6926, respectively). The observations in both groups are in line with the change in relative abundance (Figure 3B), where a remarkable increase in *Lactobacillus* and a small decrease in *Blautia* between the blank samples and the samples taken during the study was shown. However, in the cefquinome group, *Papillibacter* exhibited the strongest correlation (R^2 0.7606) but is thought to be less important due to its low level of abundance within the microbial community ($\pm 1\%$).

Impact on antibiotic resistome profiling

Antibiotic resistome profiling of the porcine fecal samples depicted that, regardless of the treatment with antibiotics, all samples contained a diverse, but comparable set of ARGs (Figure 6). The two most predominant classes of ARGs were directed to either tetracyclines (mean = 33.64 ± 8.98 throughout the study) or macrolide-lincosamides-streptogramins (MLS) (mean 30.24 ± 14.98 throughout the study), followed by ARGs against oxazolidinone and macrolides alone.

Differential abundance analysis revealed a significant increase (FDR-corrected P -value ≤ 0.10) in ARGs in the samples but only immediately at the end of the treatment (Table 1). In both the ceftiofur and cefquinome group, ARGs directed against tetracyclines (*tetQ* and *tet(40)*) showed an increase in abundance. However, for cefquinome, several other ARGs showed an increase in abundance, such as *lsaB* (multi-drug ABC efflux pumps), *ErmF* (23S rRNA methyltransferases), *CfxA6* (Class A beta-lactamases) and *mel* (Macrolides Lincosamides Streptogramins resistance Major Facilitator Superfamily efflux pumps). The most strongly increased ARGs in the cefquinome treated group were *mel* and *tetQ* with an approximately 2.5 log₂ fold change. Important to note, no ARGs showed a decrease in abundance after the administration of either cefquinome or ceftiofur. Furthermore, our data suggested that within one week after cessation of the antibacterial treatment, the ARG resistome recovered to the same level as the control group, as no significant differential abundance in ARGs between the control group and either the ceftiofur or cefquinome group could be observed.




Figure 6 Relative abundance of the top 10 classes of antibiotics to which most ARGs in porcine fecal samples are directed against, during the study. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days. (BT = Before-treatment, ET = End of Treatment, 7d = 7 days post-treatment, 21d = 21 days post-treatment).

Table 1 Differential abundance analysis of the antibiotic resistance genes in the porcine fecal samples

| | ARG | baseMean | Log ₂ Foldchange | q-value | Mechanism |
|------------|----------------|----------|-----------------------------|---------|---|
| Ceftiofur | <i>tetQ</i> | 6.27 | 2.14 | 0.05 | Tetracycline resistance ribosomal protection proteins |
| Cefquinome | <i>mel</i> | 8.51 | 2.58 | 0.00 | MLS resistance MFS efflux pumps |
| | <i>tetQ</i> | 8.33 | 2.54 | 0.00 | Tetracycline resistance ribosomal protection proteins |
| | <i>ErmF</i> | 7.81 | 2.43 | 0.00 | 23S rRNA methyltransferases |
| | <i>CfxA6</i> | 4.21 | 2.16 | 0.03 | Class A beta-lactamases |
| | <i>IsaB</i> | 7.71 | 1.76 | 0.02 | Multi-drug ABC efflux pumps |
| | <i>tet(40)</i> | 7.37 | 1.68 | 0.03 | Tetracycline resistance ribosomal protection proteins |

Comparison of samples collected immediately after treatment (ET) with either ceftiofur (3 mg.kg⁻¹ intramuscular, 3 consecutive days) or cefquinome (2 mg.kg⁻¹ intramuscular, 5 consecutive days) to those collected from the control group at the same timepoint.

Resistome profile variations

Permutational multivariate analysis of variance using the Bray Curtis distance matrix indicated a significant variation of 45.50% in profile of ARGs counts at the end of treatment (Adonis R², FDR-corrected *P*-value 0.0720) that could be explained by cefquinome treatment (ET_Cont vs ET_CQ) (Additional file 7). This is in agreement with the corresponding PCoA which displays a clear separation of the samples collected from the cefquinome group as compared to the control group (Figure 7B). On the other hand, animals that received ceftiofur showed no significant impact on the ARG counts profile at the end of treatment (Adonis R² 0.2257, FDR-corrected *P*-value 0.1898). For cefquinome, the observed difference could no longer be detected in the samples taken 7 days and 21 days pt. However, at 7 dpt a wide dispersion of the samples from the cefquinome group could still be observed (Figure 7C). Although the overall effect of cefquinome treatment on that timepoint was not significantly different than in the control group, this dispersion indicated that cefquinome administration potentially contributed to a wide variety of effects, which might be animal dependent. At 21 dpt, the antimicrobial resistome profile of all three groups was comparable again (Figure 7D).

Correlation-coefficient analysis of the different sampling points resulted in a list of influential antimicrobial resistance genes that drove the observed divergence among datapoints (Additional file 8, R²>0.4 cut-off). Before-treatment the most influential ARGs were *tetQ* and *tetW* (tetracycline resistance ribosomal protection proteins), *CfxA6* (Class A beta-lactamase) and *IsaB* (Multi-drug ABC efflux pump). Immediately after treatment cessation and up until 7 dpt, *ErmB* (23S rRNA methyltransferase) became the most influential ARG, mainly driving the ceftiofur group, which is also visualized in Figure 7B and Figure 7C. Interestingly, *ErmB* was shown to be plasmid-borne in both *Lactobacillus* and *Limosilactobacillus* species. In the case of

Lactobacillus-associated *ErmB*, the same repUS69 replicon (with closest match to the pRKC30SC1 plasmid (CP002560)) was identified on the same read for all the samples. Also for three *Limosilactobacillus* classified read bins, a match with the repUS69 replicon was found, but now with a closest match to the pTE44 plasmid (AY082384). Cefquinome divergence was driven by *mel* both at end of treatment and at 21 days post-treatment. The importance of *mel* as a driving force within the cefquinome group is in line with the results obtained from the differential abundance analysis. Finally, only two other ARG-encoding plasmids were identified in current dataset, including the *tetK* and *mcr4.2* genes in *Staphylococcus* (sample 1–0004918) and *Escherichia* species (sample 1–0004930). These were present on a plasmid carrying a rep7a replicon cassette (AB037671) and ColE10 replicon (X01654), respectively.

Antimicrobial resistance genes—genus allocation

Figure 8 depicts an overview of the changes in resistance genes that resulted in a significant log₂ fold change. The advantage of long-read shotgun sequencing is the possibility to allocate the observed ARGs to a corresponding genus. In order to interpret the results properly, an assumption was made that samples resulting in lower or higher base counts, still represented a homogenous microbial environment. Also, the ARGs counts were corrected to 1.000.000.000 base-counts per sample. The most strongly increased ARG in the fecal samples of the cefquinome treatment group was *mel*, which is mainly associated with *Bacteroides* in all groups. Figure 8A depicts a decrease of *mel* in the cefquinome group at 21 dpt, while the relative abundance of *Bacteroides* in the shotgun sequencing dataset remained stable during the entire treatment period (Additional file 9). For ceftiofur, this decrease was not observed, while also the relative abundance remained stable. In the control group at the end of the treatment sampling point (ET) there was a decrease in resistance genes allocated to *Bacteroides*




Figure 7 Principal Coordinates Analysis (PCoA) using the Bray–Curtis dissimilarity index showing the change in resistome profile.

A Change in resistome profile before-treatment. **B** Change in resistome profile at the end of treatment. **C** Change in resistome profile 7 days post-treatment. **D** Change in resistome profile 21 days post-treatment. The arrows depict a significant influential ARG with $R^2 > 0.4$ at the observed timepoint for that quadrant (if present). Following either ceftiofur treatment: 3 mg.kg^{-1} intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg^{-1} intramuscular, 5 consecutive days.

(Figures 8A, B and C) and *Prevotella* (Figures 8B and D). This general decrease is in line with the decline in relative abundance of these two genera (shotgun data, Additional file 9) at the corresponding sampling point and can thus be explained by normal fluctuations. For cefquinome and ceftiofur, no such decline in relative abundance (shotgun data, Additional file 9) could be observed between the before-treatment levels and those at end of treatment. In contrast, the 21 dpt sampling point in the control group showed overall high ARG counts, while the relative abundance was lower in comparison to the before-treatment sampling point, especially for *Prevotella*. This suggested beneficial properties over time of *Bacteroides*

and *Prevotella* harbouring ARGs in contrast to these genera without the ARGs even without the exposure to an antimicrobial. The second important resistance gene, *tetQ*, was associated with both *Prevotella* and *Bacteroides* (Figure 8B). For *tetQ* associated with *Prevotella* the ARG counts followed the changes in relative abundance, so treatment and/or time did not impact the *tetQ*-*Prevotella* ratio. However, for *tetQ* associated with *Bacteroides*, the data suggested a potential selective effect caused by ceftiofur treatment, since here a comparable relative abundance of *Bacteroides* on the 7 dpt sampling point and the before-treatment sampling point was observed. Though, an increase in corrected base counts for *tetQ* was also




Figure 8 Mean resistance gene counts corrected to the base counts of the six resistance genes. Bar plots (+ standard deviation) showing the mean resistance gene counts with a significant \log_2 fold change of each sample corrected to the base counts following either ceftiofur treatment: 3 mg.kg^{-1} intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg^{-1} intramuscular, 5 consecutive days. (BT = Before-treatment, ET = End of Treatment, 7d = 7 days post-treatment, 21d = 21 days post-treatment).

seen. In the cefquinome treatment group, the fluctuations of *tetQ* followed those of the relative abundance of *Bacteroides*. The third resistance gene, *ErmF* (Figure 8C), was associated with *Bacteroides* and followed the relative

abundance fluctuations in all the groups. The next ARG, *CfxA6*, a class A beta-lactamase associated gene, was in this study mainly associated with *Prevotella* and showed no change after cefquinome treatment, since there was

both a decrease in ARG counts as in relative abundance of *Prevotella* (Figure 8D). In contrast, in the ceftiofur group, especially on 7 dpt, there was a noticeable increase in *CfxA6* counts, while the relative abundance of *Prevotella* was comparable to that of the other groups. This suggested a selection of *Prevotella* harbouring *CfxA6* after ceftiofur treatment. The next ARG that exhibited a significant log₂ fold change is *lsaB*, which was associated with *Roseburia* (Figure 8E). The most remarkable change could be seen in the cefquinome group, where a decrease in *lsaB* counts between the 7 days and 21 dpt sampling point was seen, with no apparent decrease in relative abundance. The last resistance gene was *tet(40)* and was mainly associated with *Faecalibacterium*, *Roseburia*, and *Clostridium* (Figure 8F). The changes of *tet(40)* in *Faecalibacterium* and *Roseburia* could be attributed to normal fluctuations, since for all groups the same patterns could be detected. For *tet(40)* on *Clostridium* there was a small increase of ARG counts between 7 and 21 days post ceftiofur treatment, while the relative abundance between these two days remained stable. This suggested a possible selection of *tet(40)* associated *Clostridium* after ceftiofur treatment. The long-read shotgun sequencing data resulted in another interesting finding in the ceftiofur treatment group. In this group an increase of a plasmid-mediated beta-lactamase, *bla*_{TEM-1}, associated with *Escherichia* could be observed mainly on day 7 but also on day 21 pt, on the other two timepoints no *bla*_{TEM-1} was detected.

Discussion

In this study, we assessed the impact of the administration of either ceftiofur or cefquinome (as instructed on the manufacturers' leaflet) on the pig fecal microbiota and associated resistome over time by applying both 16S rRNA gene and shotgun sequencing.

We report no significant alterations in the evenness of the α -diversity (Shannon index) in the control and ceftiofur group [36]. In the human gut microbiota an increase in bacterial diversity from birth up to approximately 3 years has been reported, whereafter it reaches a fluctuating but relatively stable status [37]. The same has been observed in micro-pigs and conventional pigs, where a stable community is established approximately 2–3 weeks post-weaning [38, 39]. The reported non-significant changes in α -diversity observed in our study could, therefore, be attributed to normal fluctuations. For cefquinome, a significant decrease in α -diversity was observed in the samples collected 7 dpt followed by a recovery to the initial levels measured at the end of treatment by 21 dpt. However, these levels were still within the same range as for the control and ceftiofur group and are, therefore, considered to be of no notable importance.

Concerning the fecal microbiome, our study indicated that approximately 90% of the observed genera belonged to the Firmicutes phylum on all sampling days (prior and post-treatment). This is in line with the previously observed abundance of Firmicutes in the gut microbiome during the growing phase of pigs [38, 40, 41]. Firmicutes bacteria can ferment carbohydrates to short-chain fatty acids, which play an important role in the intestinal barrier function and are thus essential members of the gastro-intestinal tract of mammals [42]. However, the dominance of Firmicutes competes with that of Bacteroidetes, which was the most abundant phylum in several other studies [43, 44]. These observed discrepancies in the pig fecal microbiome may be the result of the different environments and diets to which the examined animals were exposed [45, 46]. Also, the use of nanopore long-read and not old-school V3-V4 16S rRNA gene sequencing might have contributed to differences from what has been observed before. Though, using full-length 16S rRNA gene sequences was shown to provide an analytical advantage [47]. Figure 3A showed that the abundance of Firmicutes decreased in favour of Bacteroidetes 21 days after the end of the conventional cefquinome treatment. Bacteroidetes members are known to negatively correlate with body weight in several mammals, including pigs [48, 49]. This means that administration of cefquinome might result in leaner pigs and thus a higher feed conversion ratio. In the current study, the weight of the pigs was not assessed, so this could not be confirmed.

Both ceftiofur and cefquinome treatment resulted in an overall increase in members of the Proteobacteria phylum in comparison to the control (Figure 4). Especially between the 7 dpt and the 21 dpt sampling point, a significant log₂ fold change associated with an increase in Proteobacteria members was detected. This observed increase in relative abundance of Proteobacteria only after treatment with antimicrobials might be caused by the ARG carrying nature of this phylum. It has been reported before that antimicrobial treatment causes an increase in Proteobacteria and enriches the ARGs in this phylum, driving the ARG burden only further [50, 51]. Furthermore, the Proteobacteria phylum contains several potential opportunistic pathogens, such as *Escherichia* and *Helicobacter*. The increase in this phylum could, therefore, indicate a negative impact on overall gut health caused by antimicrobial treatment [52].

Only treatment with cefquinome increased some samples in *Elusimicrobium* 21 dpt. Members of the Elusimicrobia phylum are capable of producing H₂, and are involved in the fermentative function of the gut. However, it is not clear whether or not their presence is beneficial for the host's health [53, 54]. Since only a small subset of samples in the cefquinome group exhibited

this increase, further research is required to investigate whether this finding is caused by cefquinome treatment or an observation of coincidence.

Interestingly, an increase in two members of the PVC (Planctomycetota, Verrucomicrobiota, and Chlamydiota) superphylum, Kiritimatiellaeota and Lentisphaerae, was observed only in the control group 21 dpt. These two phyla have been detected in the intestines of mammals, however, their function remains rather unclear [55]. For Lentisphaerae, their presence has been associated with a healthier gut microbiome in humans and weight gain in cattle [56]. An increase in these phyla might, therefore, suggest a healthier gut in comparison to the gut health of the pigs treated with either ceftiofur or cefquinome.

On family level, members of Lachnospiraceae (*Blautia*), Ruminococcaceae, Clostridiaceae (*Clostridium*) and Lactobacillaceae (*Lactobacillus*) were of relatively high abundance. The presence of these families is generally deemed beneficial during growth. The bacterial populations affiliated with Lachnospiraceae, Ruminococcaceae and Clostridiaceae can express enzymes that are associated with butyrate production and are thus important in the energy production necessary in growing pigs [57, 58]. Members of Lactobacillaceae, on the other hand, inhibit and prevent the growth of pathogens in the gastro-intestinal tract and some of its members can enhance the gut inflammatory response [59, 60].

It was demonstrated that by the end of treatment with cefquinome a decrease in *Lactobacillus* was observed associated with an increase in *Christensenella* and *Oscillibacter*. *Lactobacillus* is considered an important member of the gut microbiome and is often applied as a probiotic in pig industry [61]. Nevertheless, the presence of *Christensenella* and *Oscillibacter* has been associated with leaner and healthier pigs that are more feed-efficient [62, 63]. Thus overall, this change does not imply a detrimental impact on the piglet's health.

A remarkable finding was the decrease of *Clostridium* members in the cefquinome group 21 days post-treatment, while in both control and ceftiofur group a steady increase over time was observed. The most abundant members were *C. tertium*, *C. disporicum* and *C. saudiense* (as identified by full-length 16S rRNA sequences), the first two being associated with serious cases of infection [64, 65]. Administration of cefquinome could, therefore, have a collateral beneficial impact on the gut *Clostridium* load. Further research should confirm or disprove this finding.

In our previous study, shotgun sequencing was applied to investigate both the effect of conventional ceftiofur administration on the microbiome as well as on the resistome in pig feces instead of 16S rRNA analysis [16]. Consequently, when comparing the microbiome results

of this previous study and the current study, some discrepancies emerged. For example, with shotgun analysis, an increase in *Prevotella* was observed, while in this study no significant changes in *Prevotella* abundance could be detected. Furthermore, by including a control group in the current study, observations made in the previous study, such as the increase in *Blautia* abundance, could now be attributed to normal day-to-day fluctuations. Both shotgun sequencing and 16S rRNA gene sequencing have their own biases and pitfalls, which of these two methods is preferable over the other depends on the proposed research question [47, 66–68]. Typically, for taxonomic compositional analysis, 16S rRNA is considered the gold standard [69]. Therefore, the compositional results obtained in the current study are considered more useful to derive conclusions from than those from our previous study. However, it remains imperative to stress that when drawing conclusions from sequencing data, the results obtained via 16S rRNA gene sequencing (PCR amplification using conserved primers) and those from shotgun sequencing (no amplification) are not directly comparable and that it is important to be aware of the technique applied in each study. Still, differences in studies could also be attributed to the presence of ARGs on mobile genetic elements, such as plasmids. Our study showed the high prevalence of an *ErmB*-harbouring plasmid with repUS69 replicon in *Lactobacillus* and *Limosilactobacillus* species. Surprisingly, only two other plasmid borne ARGs could be identified, being *tetK* and *mcr4.2* within *Staphylococcus* and *Escherichia* classified reads, respectively. While the used library preparation (RBK-004) was shown to be favourable in studying plasmid sequences, sequencing throughput (241 326 (\pm 121.660) reads), sample complexity (i.e., fecal samples), read length N_{50} values (4023 (\pm 893) nucleotides), and clinical-focused replicon databases (e.g., PlasmidFinder) might pose a limitation to current investigations on plasmid sequences from shotgun sequencing data.

Overall, cefquinome treatment had a more substantial impact on the microbiome in comparison to ceftiofur treatment, with more than double the number of affected genera (18 vs 8, respectively). This was confirmed by the PCoA results (Figure 5B) that showed a clear impact of cefquinome treatment immediately post-treatment when compared to the microbiome composition of the control group.

The antibiotic resistome profiling revealed the presence of a diverse set of resistance genes in the fecal microbiome of pigs, even without the presence of antimicrobial pressure. Following other results in human, chicken, and pig samples, a relatively high abundance of ARGs associated with tetracycline and

macrolide-lincosamide-streptogramin (MLS) was detected, with those directed against tetracyclines being the most abundant [70]. To the authors' knowledge, there is no publicly available shotgun metagenomic data on the effect of either ceftiofur or cefquinome administration on the gastrointestinal resistome in pigs over time.

This study revealed a detectable increase in several ARGs immediately after treatment with either ceftiofur or cefquinome. After ceftiofur treatment, only one resistance gene was increased (*tetQ*). Conventional treatment with cefquinome, on the other hand, resulted in an increase of six ARGs, of which one was associated with resistance against beta-lactam antibiotics (i.e. *CfxA6*). The selection of non-associated ARGs, i.e. ARGs not directed against the applied antimicrobial, has been observed previously following treatment with antimicrobial agents belonging to different antimicrobial classes [71, 72]. A possible explanation for this observed collateral selection might be the association of the enriched genes with mobile genetic elements [73, 74]. This co-selection emphasizes the need to monitor the effect of antimicrobial treatment on multiple ARGs, even those not associated with the applied antimicrobial agent. As visually confirmed by the PCoA (Figure 7B), only cefquinome treatment exhibited a significant effect on the overall gut resistome in pigs immediately after treatment, mostly driven by the increase of the *mel* resistance gene.

Long-read shotgun sequencing allowed correlation of the ARGs with a significant \log_2 fold change to their corresponding genus. The most important resistance genes (i.e. *tetQ* and *CfxA6*) were mostly associated with either *Prevotella* and/or *Bacteroides*. This is in line with our previous study, where *Prevotella* and *Bacteroides* were the main genera of interest [16].

Following ceftiofur treatment, a selection of *tetQ* containing *Bacteroides* and of *CfxA6* containing *Prevotella* was observed. This increase of *CfxA6* on *Prevotella* is in contrast with our previous study, where an increase of *CfxA6* on *Bacteroides* instead of on *Prevotella* was observed. However, in the previous study, the level of *CfxA6* on *Prevotella* was already low to begin with, while in the current study it was the other way around, with *Bacteroides* containing only low levels of *CfxA6* at the start of the experiment. Moreover, our preliminary study was composed of fewer data points. Combining the results of the previous study and the current study, it can be concluded that rather the presence of the ARGs on a certain genus influences its selection than that the observed selection is the result of the presence of the specific genus.

Another remarkable finding caused by ceftiofur treatment was the appearance of *bla*_{TEM-1} associated *E. coli* (as determined by full-length 16S rRNA gene).

Throughout the study an increase in *Escherichia* and an appearance of *bla*_{TEM-1} in the samples taken 7 and 21 dpt was observed (not significant). It is known that the majority of *E. coli*'s carry a *bla*_{TEM-1} resistance gene and that later generations (i.e. the 4th and 5th generation) of cephalosporins, such as cefquinome, are not affected by the *bla*_{TEM-1} beta-lactamases [75]. Therefore, it could be that the inability to detect this gene in the before and end of treatment ceftiofur samples is rather caused by the low abundance of *E. coli* ($\pm 0.3\%$) at the beginning of the experiment than by the true absence of *bla*_{TEM-1}, and that cefquinome treatment does not impact its prevalence, hence no detection of *bla*_{TEM-1} associated *E. coli* in the cefquinome samples. The increase in both *bla*_{TEM-1} and *Escherichia* following ceftiofur treatment suggests a selection because of this administration. It would be interesting to investigate this finding further, since, although *bla*_{TEM-1} is not considered an ESBL, it can be transformed into an ESBL through mutations of the amino acid sequence around its active site [76]. The increase of *bla*_{TEM-1} and *CfxA* following the intramuscular administration of ceftiofur has been observed before in cattle treated with a combination of intramuscularly administered ceftiofur and intramammary administered cefquinome. In the same study on cattle, also a decrease in *Clostridium* members was observed, which might be caused by cefquinome, as observed in our study in pigs [77].

In contrast to the results of the differential abundance analysis and the PCoA (Figure 7B) from the cefquinome treatment group, correlating the ARGs of interest with their corresponding genera did not result in notable findings. Some increases and decreases were observed but did not seem to be of any importance. For example, *CfxA6*, the only cephalosporin-specific resistance gene that showed a significant \log_2 fold change, did not exhibit the same alterations on *Prevotella* as it did following ceftiofur treatment. It can, therefore, be concluded that cefquinome had a more general impact on the resistome instead of a more selective impact, as was observed for ceftiofur.

In general, the data suggests that the impact on gut resistome level for both cefquinome and ceftiofur is the most pronounced immediately following treatment (ET) with a return to the same levels as the control group by 21 days post-treatment. Further research is required to evaluate the functionality of the resistome (i.e. the gene expression), since it has been reported that only around 60% of all identified ARGs get expressed, and thus examining the composition of the resistome only shows a part of the impact of antimicrobial administration [78]. Also, the impact on other AMR mechanisms (i.e. point mutations within rRNA and/or *ParC/GyrA* genes) should

be addressed as the landscape of acquired resistance is highly complex [79].

In this study, we investigated the impact of conventional treatment with either ceftiofur or cefquinome on the porcine gut microbiome and resistome in clinically healthy pigs, by applying a combination of 16S rRNA gene and shotgun sequencing. Our results suggest that the administration of cefquinome has a more substantial impact on the microbiome and general resistome of porcine fecal samples in comparison to the administration of ceftiofur. However, ceftiofur treatment seems to have a more specific impact on resistome alteration (i.e. selection of cephalosporin-specific associated ARGs). These findings provide more information on the collateral effect of the conventional treatment schedule of these important antimicrobials and can be used to formulate well-founded treatment decisions in the future.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13567-023-01176-8>.

Additional file 1: Overview of the 16S rRNA sequencing results for all samples. 16S rRNA sequencing results following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days. The raw sequencing datafiles are available on the European Nucleotide Archive under project PRJEB61541 and accessions ERS1494721-ERS1494789.

Additional file 2: Overview of the shotgun sequencing results for all samples. Shotgun sequencing results following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Additional file 3: Rarefaction curves showing the taxon richness at genus level in function of the sequencing depth for each sample. A. Rarefaction curves of the control group. B. Rarefaction curves of the ceftiofur group. C. Rarefaction curves of the cefquinome group. The grey dotted line depicts the cut-off used to correct for difference in sequencing depth during down-stream analysis. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Additional file 4: Differential abundance analysis of the microbial genera in the porcine fecal samples. Differential abundance analysis of the microbial genera that exhibited significantly increased/decreased abundances due to time and/or ceftiofur or cefquinome administration across different sampling points. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Additional file 5: Pairwise comparison for Permutational Multivariate Analysis of Variance using Bray-Curtis dissimilarity index. PERMANOVA of the ceftiofur group to either the blank samples, to the control samples at the same sampling point or to the different timepoints within the ceftiofur group and of the cefquinome group to either the control group, to the control samples at the same sampling point or to the different timepoints within the cefquinome group. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Additional file 6: Correlation-coefficient analysis of the top 21 most abundant microbial genera in the porcine fecal samples.

Additional file 7: Pairwise comparison for Permutational Multivariate Analysis of Variance using Bray-Curtis dissimilarity index of the antimicrobial resistance genes. PERMANOVA of the antimicrobial resistance

genes of each treatment group at each sampling point in comparison to the control group. Following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Additional file 8: Correlation-coefficient analysis of the antimicrobial resistance genes. Correlation-coefficient analysis of the antimicrobial resistance genes in the porcine fecal samples with an R2 value greater than 0.4 at each sampling point.

Additional file 9: Relative abundance of genera associated with the antimicrobial resistance genes. Relative abundance of genera associated with the antimicrobial resistance genes that exhibit a significant log₂-fold change following either ceftiofur treatment: 3 mg.kg⁻¹ intramuscular, 3 consecutive days or cefquinome treatment: 2 mg.kg⁻¹ intramuscular, 5 consecutive days.

Acknowledgements

The assistance of Danica den Hollander, Eline Hermans, Kaat Neckermann, Celestien Holvoet, Despoina Georgaki, and Caro Vervaeke for help during the animal experiment is gratefully acknowledged. Thanks to Marthe Pauwels for help with the nanopore sequencing.

Authors' contributions

Conceptualization, SR, SC and MD; formal analysis, SR, NV and JS; investigation, SR; data curation, SR; writing—original draft preparation, SR; writing—review and editing, SR, NV, SC and MD; visualization, SR, NV and JS; project administration, SR. All authors read and approved the final manuscript.

Funding

This research received no external funding. N.V. was supported by a Grant from the Flemish Agency for Innovation and Entrepreneurship (Grant HBC.2020.2889); N.V. is a PhD student at PathoSense BV and Ghent University.

Availability of data and materials

The raw data supporting the conclusions of this article are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committee of the Faculty of Veterinary Medicine and the Faculty of Bioscience Engineering of Ghent University (Approval number EC 2021–107, Approved 14 February 2022).

Competing interests

The authors declare that they have no competing interests.

Received: 17 February 2023 Accepted: 10 May 2023

Published online: 06 June 2023

References

- Dadgostar P (2019) Antimicrobial resistance: implications and costs. *Infect Drug Resist* 12:3903–3910
- WHO (2014) Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva
- Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M (2020) Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. *Infect Drug Resist* 13:4713–4738
- EFSA (2023) The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2020/2021. *EFSA J* 21:e07867
- WHO (2019) Critically important antimicrobials for human medicine. World Health Organization, Geneva

6. Collignon PC, Conly JM, Andreumont A, McEwen SA, Aidara-Kane A, for the World Health Organization Advisory Group BMolSoAR, Agerso Y, Andreumont A, Collignon P, Conly J, Dang Ninh T, Donado-Godoy P, Fedorka-Cray P, Fernandez H, Galas M, Irwin R, Karp B, Matar G, McDermott P, McEwen S, Mitema E, Reid-Smith R, Scott HM, Singh R, DeWaal CS, Stelling J, Toleman M, Watanabe H, Woo GJ (2016) World Health Organization ranking of antimicrobials according to their importance in human medicine: a critical step for developing risk management strategies to control antimicrobial resistance from food animal production. *Clin Infect Dis* 63:1093
7. Seiffert SN, Hilty M, Perreten V, Endimiani A (2013) Extended-spectrum cephalosporin-resistant gram-negative organisms in livestock: an emerging problem for human health? *Drug Resist Updat* 16:22–45
8. Geenen PL, Koene M, Blaak H, Havelaar AH, Van de Giessen A (2011) Risk profile on antimicrobial resistance transmissible from food animals to humans. Report <https://www.rivm.nl/bibliotheek/rapporten/330334001.pdf>
9. Garcia-Migura L, Hendriksen RS, Fraile L, Aarestrup FM (2014) Antimicrobial resistance of zoonotic and commensal bacteria in Europe: The missing link between consumption and resistance in veterinary medicine. *Vet Microbiol* 170:1–9
10. Hiki M, Kawanishi M, Abo H, Kojima A, Koike R, Hamamoto S, Asai T (2015) Decreased resistance to broad-spectrum cephalosporin in *Escherichia coli* from healthy broilers at farms in Japan after voluntary withdrawal of ceftiofur. *Foodborne Pathog Dis* 12:639–643
11. Agersø Y, Aarestrup FM (2012) Voluntary ban on cephalosporin use in Danish pig production has effectively reduced extended-spectrum cephalosporinase-producing *Escherichia coli* in slaughter pigs. *J Antimicrob Chemother* 68:569–572
12. Erskine RJ, Bartlett PC, VanLente JL, Phipps CR (2002) Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. *J Dairy Sci* 85:2571–2575
13. Scientific Advisory Group on Antimicrobials of the Committee for Medicinal Products for Veterinary Use (2009) Reflection paper on the use of third and fourth generation cephalosporins in food producing animals in the European Union: development of resistance and impact on human and animal health. *J Vet Pharmacol Ther* 32:515–533
14. AMCR (2014) Formularium voor verantwoord gebruik van antibacteriële middelen in de varkenshouderij. <https://formularium.amcr.be/a/3>. Accessed 11 Jan 2023
15. Lhermie G, La Ragione RM, Weese JS, Olsen JE, Christensen JP, Guardabassi L (2020) Indications for the use of highest priority critically important antimicrobials in the veterinary sector. *J Antimicrob Chemother* 75:1671–1680
16. Rutjens S, Vereecke N, De Spiegelaere W, Croubels S, Devreese M (2022) Intestinal exposure to ceftiofur and cefquinome after intramuscular treatment and the impact of ceftiofur on the pig fecal microbiome and resistance. *Antibiotics* 11:342
17. Andersen VD, Jensen VF, Vigre H, Andreasen M, Agersø Y (2015) The use of third and fourth generation cephalosporins affects the occurrence of extended-spectrum cephalosporinase-producing *Escherichia coli* in Danish pig herds. *Vet J* 204:345–350
18. Cameron-Veas K, Moreno MA, Fraile L, Migura-Garcia L (2016) Shedding of cephalosporin resistant *Escherichia coli* in pigs from conventional farms after early treatment with antimicrobials. *Vet J* 211:21–25
19. Gregova G, Kmet V (2020) Antibiotic resistance and virulence of *Escherichia coli* strains isolated from animal rendering plant. *Sci Rep* 10:17108
20. Ruczizka U, Metzler-Zebeli B, Unterwiesing C, Mann E, Schwarz L, Knecht C, Hennig-Pauka I (2020) Early parenteral administration of ceftiofur has gender-specific short- and long-term effects on the fecal microbiota and growth in pigs from the suckling to growing phase. *Animals* 10:17
21. Nowland TL, Torok VA, Low WY, Barton MD, Plush KJ, Kirkwood RN (2020) Faecal microbiota analysis of piglets during lactation. *Animals* 10:762
22. Fleury M, Mourand G, Jouy E, Touzain F, Le Devendec L, De Boisseson C, Eono F, Cariolet R, Guerin A, Le Goff O (2015) Impact of ceftiofur injection on gut microbiota and *Escherichia coli* resistance in pigs. *Antimicrob Agents Chemother* 59:5171–5180
23. Flemish Government (2017) Flemish Decree of 17 february 2017 on the amendment of the Belgian Royal Decree of 29 May 2013 on the protection of animals used for scientific purposes and the Belgian Royal Decree of 21 November 1996 for the determination of compensation of transport and accommodation costs for persons not belonging to the Administration and part of some bodies put together for the Royal Decree of 14 August 1986 concerning the protection and welfare of animals. *Belgisch Staatsblad* 170:115
24. EU (2010) Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Official J Eur Union
25. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO (2012) The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res* 41:D590–D596
26. Curry KD, Wang Q, Nute MG, Tyshiaeva A, Reeves E, Soriano S, Wu Q, Graeber E, Finzer P, Mendling W, Savidge T, Villapal S, Diltthey A, Treangen TJ (2022) Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. *Nat Methods* 19:845–853
27. De Coster W, D'Hert S, Schultz DT, Cruys M, Van Broeckhoven C (2018) NanoPack: visualizing and processing long-read sequencing data. *Bioinformatics* 34:2666–2669
28. Wood DE, Lu J, Langmead B (2019) Improved metagenomic analysis with Kraken 2. *Genome Biol* 20:257
29. Alcock BP, Raphenya AR, Lau TT, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen A-LV, Cheng AA, Liu S (2020) CARD 2020: antibiotic resistance surveillance with the comprehensive antibiotic resistance database. *Nucleic Acids Res* 48:D517–D525
30. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H (2014) In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903
31. Seemann T (2023) Abricate. In. <https://github.com/tseemann/abricate>
32. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550
33. Gu Z, Eils R, Schlesner M (2016) Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32:2847–2849
34. Oksanen J, Blanchet FG, Kindt R, Legendre P, Minchin PR, O'hara R, Simpson GL, Solymos P, Stevens MHH, Wagner H (2013) Package 'vegan'. *Commun Ecol Package Vers* 2:1–295
35. Wickham H (2016) Package 'ggplot2': elegant graphics for data analysis. Springer 10:978–970
36. Calle ML (2019) Statistical analysis of metagenomics data. *Genomics inform* 17:6
37. Lim MY, Song E-J, Kang KS, Nam Y-D (2019) Age-related compositional and functional changes in micro-pig gut microbiome. *GeroScience* 41:935–944
38. Slifierz MJ, Friendship RM, Weese JS (2015) Longitudinal study of the early-life fecal and nasal microbiotas of the domestic pig. *BMC Microbiol* 15:184
39. Ke S, Fang S, He M, Huang X, Yang H, Yang B, Chen C, Huang L (2019) Age-based dynamic changes of phylogenetic composition and interaction networks of health pig gut microbiome feeding in a uniformed condition. *BMC Vet Res* 15:172
40. Kim J, Nguyen SG, Guevarra RB, Lee I, Unno T (2015) Analysis of swine fecal microbiota at various growth stages. *Arch Microbiol* 197:753–759
41. Han GG, Lee J-Y, Jin G-D, Park J, Choi YH, Kang S-K, Chae BJ, Kim EB, Choi Y-J (2018) Tracing of the fecal microbiota of commercial pigs at five growth stages from birth to shipment. *Sci Rep* 8:6012
42. Huang Y, Shi X, Li Z, Shen Y, Shi X, Wang L, Li G, Yuan Y, Wang J, Zhang Y, Zhao L, Zhang M, Kang Y, Liang Y (2018) Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder. *Neuropsychiatr Dis Treat* 14:3329–3337
43. Pajarillo EAB, Chae J-P, Balolong MP, Kim HB, Kang D-K (2014) Assessment of fecal bacterial diversity among healthy piglets during the weaning transition. *J Gen Appl Microbiol* 60:140–146
44. Hu J, Nie Y, Chen J, Zhang Y, Wang Z, Fan Q, Yan X (2016) Gradual changes of gut microbiota in weaned miniature piglets. *Front Microbiol* 7:1727
45. Thompson CL, Wang B, Holmes AJ (2008) The immediate environment during postnatal development has long-term impact on gut community structure in pigs. *ISME J* 2:739–748
46. Pluske JR (2013) Feed-and feed additives-related aspects of gut health and development in weanling pigs. *J Anim Sci Biotechnol* 4:1–7
47. Matsuo Y, Komiya S, Yasumizu Y, Yasuoka Y, Mizushima K, Takagi T, Kryukov K, Fukuda A, Morimoto Y, Naito Y, Okada H, Bono H, Nakagawa S, Hirota

- K (2021) Full-length 16S rRNA gene amplicon analysis of human gut microbiota using MinION™ nanopore sequencing confers species-level resolution. *BMC Microbiol* 21:35
48. Thomas F, Hehemann J-H, Rebuffet E, Czejek M, Michel G (2011) Environmental and gut *Bacteroidetes*: the food connection. *Front Microbiol* 2:93
 49. Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K (2008) Development of a real-time PCR method for *Firmicutes* and *Bacteroidetes* in faeces and its application to quantify intestinal population of obese and lean pigs. *Lett Appl Microbiol* 47:367–373
 50. Antonopoulos DA, Huse SM, Morrison HG, Schmidt TM, Sogin ML, Young VB (2009) Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. *Infect Immun* 77:2367–2375
 51. Hu Y, Yang X, Li J, Lv N, Liu F, Wu J, Lin IY, Wu N, Weimer BC, Gao GF, Liu Y, Zhu B (2016) The bacterial mobile resistome transfer network connecting the animal and human microbiomes. *Appl Environ Microbiol* 82:6672–6681
 52. Wu W, Zhang L, Xia B, Tang S, Xie J, Zhang H (2020) Modulation of pectin on mucosal innate immune function in pigs mediated by gut microbiota. *Microorganisms* 8:535
 53. Méheust R, Castelle CJ, Matheus Carnevali PB, Farag IF, He C, Chen L-X, Amano Y, Hug LA, Banfield JF (2020) Groundwater *Elusimicrobia* are metabolically diverse compared to gut microbiome *Elusimicrobia* and some have a novel nitrogenase paralog. *ISME J* 14:2907–2922
 54. Diao H, Yan HL, Xiao Y, Yu B, Yu J, He J, Zheng P, Zeng BH, Wei H, Mao XB, Chen DW (2016) Intestinal microbiota could transfer host Gut characteristics from pigs to mice. *BMC Microbiol* 16:238
 55. Spring S, Bunk B, Spröer C, Schumann P, Rohde M, Tindall BJ, Klenk H-P (2016) Characterization of the first cultured representative of *Verrucomicrobia* subdivision 5 indicates the proposal of a novel phylum. *ISME J* 10:2801–2816
 56. McCormack UM, Curião T, Metzler-Zebeli BU, Magowan E, Berry DP, Reyer H, Prieto ML, Buzoianu SG, Harrison M, Rebeiz N, Crispie F, Cotter PD, O'Sullivan O, Gardiner GE, Lawlor PG (2019) Porcine feed efficiency-associated intestinal microbiota and physiological traits: finding consistent cross-locational biomarkers for residual feed intake. *mSystems* 4:e00324-18
 57. Li Y, Wang X, Wang X-q, Wang J, Zhao J (2020) Life-long dynamics of the swine gut microbiome and their implications in probiotics development and food safety. *Gut Microbes* 11:1824–1832
 58. Liu H, Hou C, Li N, Zhang X, Zhang G, Yang F, Zeng X, Liu Z, Qiao S (2019) Microbial and metabolic alterations in gut microbiota of sows during pregnancy and lactation. *FASEB J* 33:4490–4501
 59. Yang F, Hou C, Zeng X, Qiao S (2015) The use of lactic acid bacteria as a probiotic in swine diets. *Pathogens* 4:34–45
 60. Vieco-Saiz N, Belguesmia Y, Raspoet R, Auclair E, Gancel F, Kempf I, Drider D (2019) Benefits and inputs from lactic acid bacteria and their bacteriocins as alternatives to antibiotic growth promoters during food-animal production. *Front Microbiol* 10:57
 61. Valeriano VDV, Balolong MP, Kang D-K (2017) Probiotic roles of *Lactobacillus* sp. in swine: insights from gut microbiota. *J Appl Microbiol* 122:554–567
 62. McCormack UM, Curião T, Buzoianu SG, Prieto ML, Ryan T, Varley P, Crispie F, Magowan E, Metzler-Zebeli BU, Berry D, O'Sullivan O, Cotter PD, Gardiner GE, Lawlor PG (2017) Exploring a possible link between the intestinal microbiota and feed efficiency in pigs. *Appl Environ Microbiol* 83:e00380-e417
 63. Jiang Q, Xie C, Chen L, Xiao H, Xie Z, Zhu X, Ma L, Yan X (2023) Identification of gut microbes associated with feed efficiency by daily-phase feeding strategy in growing-finishing pigs. *Anim Nutr* 12:42–53
 64. Guo P, Zhang K, Ma X, He P (2020) Clostridium species as probiotics: potentials and challenges. *J Anim Sci Biotechnol* 11:24
 65. Raimondi S, Musmeci E, Candelieri F, Amaretti A, Rossi M (2021) Identification of mucin degraders of the human gut microbiota. *Sci Rep* 11:11094
 66. Shah N, Tang H, Doak TG, Ye Y (2011) Comparing bacterial communities inferred from 16S rRNA gene sequencing and shotgun metagenomics. *Pac Symp Biocomput* 2011:165–176
 67. Boers SA, Jansen R, Hays JP (2019) Understanding and overcoming the pitfalls and biases of next-generation sequencing (NGS) methods for use in the routine clinical microbiological diagnostic laboratory. *Eur J Clin Microbiol Infect* 38:1059–1070
 68. Peterson D, Bonham KS, Rowland S, Pattanayak CW, RESONANCE Consortium, Klepac-Ceraj V (2021) Comparative analysis of 16S rRNA gene and metagenome sequencing in pediatric gut microbiomes. *Front Microbiol* 12:670336
 69. Santos A, van Aerle R, Barrientos L, Martinez-Urtaza J (2020) Computational methods for 16S metabarcoding studies using Nanopore sequencing data. *Comput Struct Biotechnol J* 18:296–305
 70. Joyce A, McCarthy CGP, Murphy S, Walsh F (2019) Antibiotic resistomes of healthy pig faecal metagenomes. *Microb Genom* 5:e000272
 71. Sanders CC, Sanders WE Jr, Goering RV, Werner V (1984) Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. *Antimicrob Agents Chemother* 26:797–801
 72. Tolun V, Küçükbasmacı O, Törümküney-Akbulut D, Catal C, Anđ-Küçüker M, Anđ O (2004) Relationship between ciprofloxacin resistance and extended-spectrum beta-lactamase production in *Escherichia coli* and *Klebsiella pneumoniae* strains. *Clin Microbiol Infect* 10:72–75
 73. Schroeder MR, Lohsen S, Chancey ST, Stephens DS (2019) High-level macrolide resistance due to the mega element [mef(E)/mel] in *Streptococcus pneumoniae*. *Front Microbiol* 10:868
 74. Li X, Rensing C, Vestergaard G, Arumugam M, Nesme J, Gupta S, Brejnrod AD, Sørensen SJ (2022) Metagenomic evidence for co-occurrence of antibiotic, biocide and metal resistance genes in pigs. *Environ Int* 158:106899
 75. Olesen I, Hasman H, Møller Aarestrup F (2004) Prevalence of β -lactamases among ampicillin-resistant *Escherichia coli* and *Salmonella* isolated from food animals in Denmark. *Microb Drug Resist* 10:334–340
 76. Seo KW, Shim JB, Kim YB, Son SH, Bi Noh E, Yoon S, Lim S-K, Ju Lee Y (2020) Impacts and characteristics of antimicrobial resistance of *Escherichia coli* isolates by administration of third-generation cephalosporins in layer hatcheries. *Vet Microbiol* 243:108643
 77. Dong L, Meng L, Liu H, Wu H, Schroyen M, Zheng N, Wang J (2022) Effect of cephalosporin treatment on the microbiota and antibiotic resistance genes in feces of dairy cows with clinical mastitis. *Antibiotics* 11:117
 78. Wang Y, Hu Y, Liu F, Cao J, Lv N, Zhu B, Zhang G, Gao GF (2020) Integrated metagenomic and metatranscriptomic profiling reveals differentially expressed resistomes in human, chicken, and pig gut microbiomes. *Environ Int* 138:105649
 79. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ (2015) Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol* 13:42–51

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

